与其他抗生素相比，WIN 49375对癌症患者分离菌株的体外活性。
In vitro activity of WIN 49375 compared with those of other antibiotics in isolates from cancer patients.
作者信息
Garcia I, Bodey G P, Fainstein V, Ho D H, LeBlanc B
出版信息
Antimicrob Agents Chemother. 1984 Sep;26(3):421-3. doi: 10.1128/AAC.26.3.421.
Abstract
The activity of WIN 49375 [6-fluoro-1, 4-dihydro-1-(methylamino)-7-(4-methyl-1-piperazinyl)-4-oxo-3- quinolinecarboxylic acid], a new synthetic quinolone, was tested in vitro against 587 clinical isolates. The MICs for 90% of isolates of Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae were 0.20, 1.56, and 0.39 microgram/ml, respectively. The MICs for 90% of isolates of Pseudomonas aeruginosa and Serratia marcescens were both 3.12 micrograms/ml. WIN 49375 was minimally active against gram-positive cocci. Its in vitro activity suggests that it may be useful for the treatment of gram-negative bacillary infections.
摘要
新型合成喹诺酮WIN 49375 [6-氟-1,4-二氢-1-(甲氨基)-7-(4-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸] 的活性在体外针对587株临床分离菌进行了测试。大肠杆菌、肺炎克雷伯菌和阴沟肠杆菌90% 分离株的最低抑菌浓度（MIC）分别为0.20、1.56和0.39微克/毫升。铜绿假单胞菌和粘质沙雷氏菌90% 分离株的MIC均为3.12微克/毫升。WIN 49375对革兰氏阳性球菌的活性最低。其体外活性表明它可能对治疗革兰氏阴性杆菌感染有用。
相似文献
1
In vitro activity of WIN 49375 compared with those of other antibiotics in isolates from cancer patients.与其他抗生素相比，WIN 49375对癌症患者分离菌株的体外活性。
Antimicrob Agents Chemother. 1984 Sep;26(3):421-3. doi: 10.1128/AAC.26.3.421.
2
Antibacterial activity of amifloxacin (WIN 49, 375), a new quinolone agent.
Diagn Microbiol Infect Dis. 1985 Nov;3(6):469-78. doi: 10.1016/s0732-8893(85)80003-1.
3
In vitro and in vivo antibacterial activities of the fluoroquinolone WIN 49375 (amifloxacin).氟喹诺酮类药物WIN 49375（阿米氟沙星）的体外和体内抗菌活性
Antimicrob Agents Chemother. 1985 Jan;27(1):4-10. doi: 10.1128/AAC.27.1.4.
4
In vitro activity of A-56619 and A56620, two new aryl-fluoroquinolone antimicrobial agents.两种新型芳基氟喹诺酮类抗菌剂A-56619和A-56620的体外活性
Antimicrob Agents Chemother. 1986 Feb;29(2):355-8. doi: 10.1128/AAC.29.2.355.
5
Amifloxacin activity against well-defined gentamicin-resistant, gram-negative bacteria.阿米氟沙星对明确的耐庆大霉素革兰氏阴性菌的活性。
Antimicrob Agents Chemother. 1984 Nov;26(5):781-4. doi: 10.1128/AAC.26.5.781.
6
In vitro activity of Ro 23-9424, a dual-action cephalosporin, compared with activities of other antibiotics.双效头孢菌素Ro 23-9424的体外活性与其他抗生素活性的比较
Antimicrob Agents Chemother. 1990 Feb;34(2):189-95. doi: 10.1128/AAC.34.2.189.
7
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.喹诺酮抗菌剂A - 56619和A - 56620的体外活性
Antimicrob Agents Chemother. 1985 Oct;28(4):514-20. doi: 10.1128/AAC.28.4.514.
8
In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent.新型含7-氮杂环丁烷环取代基氟喹诺酮类药物E-4868的体外及体内抗菌活性
Antimicrob Agents Chemother. 1993 Apr;37(4):868-74. doi: 10.1128/AAC.37.4.868.
9
In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients.司帕沙星（CI-978；AT-4140）对癌症患者临床分离株的体外活性。
Antimicrob Agents Chemother. 1990 Nov;34(11):2263-6. doi: 10.1128/AAC.34.11.2263.
引用本文的文献
1
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.喹诺酮抗菌剂A - 56619和A - 56620的体外活性
Antimicrob Agents Chemother. 1985 Oct;28(4):514-20. doi: 10.1128/AAC.28.4.514.
2
In vitro susceptibility of Citrobacter species to various antimicrobial agents.柠檬酸杆菌属对多种抗菌剂的体外敏感性
Antimicrob Agents Chemother. 1987 May;31(5):829-30. doi: 10.1128/AAC.31.5.829.
3
Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.亚胺培南/西司他丁。对其抗菌活性、药代动力学特性及治疗效果的综述。
Drugs. 1987 Mar;33(3):183-241. doi: 10.2165/00003495-198733030-00001.
4
Imipenem-cilastatin as initial therapy for febrile cancer patients.亚胺培南-西司他丁作为发热癌症患者的初始治疗药物。
Antimicrob Agents Chemother. 1986 Aug;30(2):211-4. doi: 10.1128/AAC.30.2.211.
5
Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.氨曲南。对其抗菌活性、药代动力学特性及治疗用途的综述。
Drugs. 1986 Feb;31(2):96-130. doi: 10.2165/00003495-198631020-00002.
6
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.氟喹诺酮类药物：结构、作用机制与耐药性以及体外活性谱
Antimicrob Agents Chemother. 1985 Oct;28(4):581-6. doi: 10.1128/AAC.28.4.581.
7
In vitro activities of amifloxacin and two of its metabolites.阿米氟沙星及其两种代谢物的体外活性。
Antimicrob Agents Chemother. 1989 May;33(5):762-6. doi: 10.1128/AAC.33.5.762.
8
Randomized, controlled trial of a 10-day course of amifloxacin versus trimethoprim-sulfamethoxazole in the treatment of acute, uncomplicated urinary tract infection. Amifloxacin Multi-Center Trial Group.阿米氟沙星与甲氧苄啶-磺胺甲恶唑治疗急性单纯性尿路感染10天疗程的随机对照试验。阿米氟沙星多中心试验组。
Antimicrob Agents Chemother. 1990 Apr;34(4):665-7. doi: 10.1128/AAC.34.4.665.
本文引用的文献
1
In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.喹诺酮羧酸依诺沙星的体外活性与诺氟沙星、新型β-内酰胺类、氨基糖苷类及甲氧苄啶的体外活性比较。
Antimicrob Agents Chemother. 1983 Nov;24(5):754-63. doi: 10.1128/AAC.24.5.754.
2
In vitro activity of ciprofloxacin (Bay o 9867).环丙沙星（拜耳o 9867）的体外活性。
Antimicrob Agents Chemother. 1983 Oct;24(4):568-74. doi: 10.1128/AAC.24.4.568.
3
Norfloxacin and the antibacterial gamma pyridone beta carboxylic acids.诺氟沙星与抗菌性γ-吡啶酮β-羧酸类化合物。
J Antimicrob Chemother. 1982 Jul;10(1):25-30. doi: 10.1093/jac/10.1.25.
4
Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates.诺氟沙星（MK-0366）与其他十种口服抗菌药物对尿细菌分离株的体外活性比较
Antimicrob Agents Chemother. 1982 May;21(5):848-51. doi: 10.1128/AAC.21.5.848.
Zotero 插件